Literature DB >> 27233294

Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.

Cen Guo1, Kyunghee Yang1, Kenneth R Brouwer1, Robert L St Claire1, Kim L R Brouwer2.   

Abstract

Transporter-mediated alterations in bile acid disposition may have significant toxicological implications. Current methods to predict interactions are limited by the interplay of multiple transporters, absence of protein in the experimental system, and inaccurate estimates of inhibitor concentrations. An integrated approach was developed to predict altered bile acid disposition due to inhibition of multiple transporters using the model bile acid taurocholate (TCA). TCA pharmacokinetic parameters were estimated by mechanistic modeling using sandwich-cultured human hepatocyte data with protein in the medium. Uptake, basolateral efflux, and biliary clearance estimates were 0.63, 0.034, and 0.074 mL/min/g liver, respectively. Cellular total TCA concentrations (Ct,Cells) were selected as the model output based on sensitivity analysis. Monte Carlo simulations of TCA Ct,Cells in the presence of model inhibitors (telmisartan and bosentan) were performed using inhibition constants for TCA transporters and inhibitor concentrations, including cellular total inhibitor concentrations ([I]t,cell) or unbound concentrations, and cytosolic total or unbound concentrations. For telmisartan, the model prediction was accurate with an average fold error (AFE) of 0.99-1.0 when unbound inhibitor concentration ([I]u) was used; accuracy dropped when total inhibitor concentration ([I]t) was used. For bosentan, AFE was 1.2-1.3 using either [I]u or [I]t This difference was evaluated by sensitivity analysis of the cellular unbound fraction of inhibitor (fu,cell,inhibitor), which revealed higher sensitivity of fu,cell,inhibitor for predicting TCA Ct,Cells when inhibitors exhibited larger ([I]t,cell/IC50) values. In conclusion, this study demonstrated the applicability of a framework to predict hepatocellular bile acid concentrations due to drug-mediated inhibition of transporters using mechanistic modeling and cytosolic or cellular unbound concentrations.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27233294      PMCID: PMC4959093          DOI: 10.1124/jpet.116.231928

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition.

Authors:  Tom De Bruyn; Wouter Sempels; Jan Snoeys; Nico Holmstock; Sagnik Chatterjee; Bruno Stieger; Patrick Augustijns; Johan Hofkens; Hideaki Mizuno; Pieter Annaert
Journal:  J Pharm Sci       Date:  2014-03-20       Impact factor: 3.534

3.  Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

Authors:  Anna-Karin Sohlenius-Sternbeck
Journal:  Toxicol In Vitro       Date:  2006-06-29       Impact factor: 3.500

4.  Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.

Authors:  Elaine M Leslie; Paul B Watkins; Richard B Kim; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2007-03-20       Impact factor: 4.030

5.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

6.  Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

Authors:  Masaru Hirano; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-04       Impact factor: 3.922

7.  Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

Authors:  Ryan E Morgan; Michael Trauner; Carlo J van Staden; Paul H Lee; Bharath Ramachandran; Michael Eschenberg; Cynthia A Afshari; Charles W Qualls; Ruth Lightfoot-Dunn; Hisham K Hamadeh
Journal:  Toxicol Sci       Date:  2010-09-09       Impact factor: 4.849

8.  Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep.

Authors:  Sachiko Mita; Hiroshi Suzuki; Hidetaka Akita; Hisamitsu Hayashi; Reiko Onuki; Alan F Hofmann; Yuichi Sugiyama
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-03       Impact factor: 4.052

9.  Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.

Authors:  Norikazu Matsunaga; Naomi Kaneko; Angelina Yukiko Staub; Takeo Nakanishi; Ken-ichi Nunoya; Haruo Imawaka; Ikumi Tamai
Journal:  Drug Metab Dispos       Date:  2015-10-26       Impact factor: 3.922

Review 10.  The complexities of hepatic drug transport: current knowledge and emerging concepts.

Authors:  Priyamvada Chandra; Kim L R Brouwer
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.580

View more
  4 in total

1.  Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors?

Authors:  Cen Guo; Kyunghee Yang; Mingxiang Liao; Cindy Q Xia; Kenneth R Brouwer; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

2.  Generation of Human Pluripotent Stem Cell-Derived Polarized Hepatocytes.

Authors:  Leila Bushweller; Yuanyuan Zhao; Fan Zhang; Xianfang Wu
Journal:  Curr Protoc       Date:  2022-01

3.  Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.

Authors:  Cen Guo; Carl LaCerte; Jeffrey E Edwards; Kenneth R Brouwer; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2018-02-27       Impact factor: 4.030

Review 4.  The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation.

Authors:  Paul B Watkins
Journal:  Clin Transl Sci       Date:  2019-03       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.